HRP20200342T1 - Derivati dihidroimidazopirazinona korisni u liječenju raka - Google Patents
Derivati dihidroimidazopirazinona korisni u liječenju raka Download PDFInfo
- Publication number
- HRP20200342T1 HRP20200342T1 HRP20200342TT HRP20200342T HRP20200342T1 HR P20200342 T1 HRP20200342 T1 HR P20200342T1 HR P20200342T T HRP20200342T T HR P20200342TT HR P20200342 T HRP20200342 T HR P20200342T HR P20200342 T1 HRP20200342 T1 HR P20200342T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- compound
- pharmaceutically acceptable
- adduct
- difluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (19)
1. Spoj s Formulom (I) ili njegov farmaceutski prihvatljiv adukt
[image]
naznačen time što:
R1 je vodik, C1-3 alkil ili -CH2OMe;
R2 je piridinil, izborno supstituiran na 1 prstenastom ugljikovom atomu sa supstituentom neovisno odabranim iz skupine koja sadrži C1-3 alkil, difluormetil i trifluormetil; ili
R2 je pirimidinil, izborno supstituiran na 1 prstenastom ugljikovom atomu sa supstituentom neovisno odabranim iz skupine koja sadrži C1-3 alkil, difluormetil i trifluormetil; ili
R2 je fenil izborno supstituiran na 1 ili 2 prstenasta ugljikova atoma sa supstituentom neovisno odabranim iz skupine koja sadrži halo, difluormetil, trifluormetil, metoksi i -OCHF2; i
R3 je vodik, C1-3 alkil ili klor.
2. Spoj s formulom (I) ili njegov farmaceutski prihvatljiv adukt, prema zahtjevu 1, naznačen time što:
R1 je vodik, metil ili -CH2OMe;
R2 je piridinil, izborno supstituiran na 1 prstenastom ugljikovom atomu sa supstituentom neovisno odabranim iz skupine koja sadrži metil, difluormetil i trifluormetil; ili
R2 je pirimidinil, izborno supstituiran na 1 prstenastom ugljikovom atomu sa supstituentom neovisno odabranim iz skupine koja sadrži metil, difluormetil i trifluormetil; ili
R2 je fenil izborno supstituiran na 1 ili 2 prstenasta ugljikova atoma sa supstituentom neovisno odabranim iz skupine koja sadrži fluor, klor, difluormetil, trifluormetil, metoksi i -OCHF2; i
R3 je vodik, metil ili klor.
3. Spoj s formulom (I) ili njegov farmaceutski prihvatljiv adukt, prema zahtjevu 1 ili zahtjevu 2, naznačen time što:
R1 je vodik, metil ili -CH2OMe;
R2 je piridinil, izborno supstituiran na 1 prstenastom ugljikovom atomu sa supstituentom neovisno odabranim iz skupine koja sadrži metil, difluormetil i trifluormetil; ili
R2 je pirimidinil, izborno supstituiran na 1 prstenastom ugljikovom atomu s trifluorometilom; ili
R2 je fenil izborno supstituiran na 1 ili 2 prstenasta ugljikova atoma sa supstituentom neovisno odabranim iz skupine koja sadrži fluor, klor, difluormetil i metoksi; i
R3 je vodik, metil ili klor.
4. Spoj kako je zatraženo u zahtjevima 1 do 3, ili njegov farmaceutski prihvatljiv adukt, naznačen time što R2 je 6-(difluormetil)piridin-2-il, 3-klorfenil, 3,4-difluorfenil ili 3,5-difluorfenil.
5. Spoj kako je zatraženo u zahtjevima 1 do 4, ili njegov farmaceutski prihvatljiv adukt, naznačen time što R2 je 6-(difluormetil)piridin-2-il.
6. Spoj kako je zatraženo u zahtjevima 1 do 4, ili njegov farmaceutski prihvatljiv adukt, naznačen time što R2 je 3-klorfenil.
7. Spoj kako je zatraženo u zahtjevima 1 do 4, ili njegov farmaceutski prihvatljiv adukt, naznačen time što R2 je 3,4-difluorfenil.
8. Spoj kako je zatraženo u zahtjevima 1 do 4, ili njegov farmaceutski prihvatljiv adukt, naznačen time što R2 je 3,5-difluorfenil.
9. Spoj prema zahtjevu 1, ili njegov farmaceutski prihvatljiv adukt, naznačen time što navedeni spoj je:
(S)-7-(3-klorbenzil)-6-metil-2-(2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)-6,7-dihidroimidazo[1,2-a]pirazin-8(5H)-on;
(S)-7-((6-(difluormetil)piridin-2-il)metil)-6-metil-2-(5-metil-2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)-6,7-dihidroimidazo[1,2-a]pirazin-8(5H)-on;
(R)-7-(3,4-difluorbenzil)-6-(metoksimetil)-2-(5-metil-2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)-6,7-dihidroimidazo[1,2-a]pirazin-8(5H)-on; ili
(S)-7-(3,5-difluorbenzil)-6-metil-2-(5-metil-2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)-6,7-dihidroimidazo[1,2-a]pirazin-8(5H)-on.
10. Spoj prema zahtjevu 1, ili njegov farmaceutski prihvatljiv adukt, naznačen time što navedeni spoj je
(R)-7-(3,4-Difluorbenzil)-6-(metoksimetil)-2-(5-metil-2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)-6,7-dihidroimidazo[1,2-a]pirazin-8(5H)-on.
11. Farmaceutski prihvatljiv adukt spoja s formulom (I) prema zahtjevu 1, naznačen time što je (R)-7-(3,4-Difluorbenzil)-6-(metoksimetil)-2-(5-metil-2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)-6,7-dihidroimidazo[1,2-a]pirazin-8(5H)-on adukt etansulfonske kiseline.
12. Kristalni oblik (R)-7-(3,4-Difluorbenzil)-6-(metoksimetil)-2-(5-metil-2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)-6,7-dihidroimidazo[1,2-a]pirazin-8(5H)-ona adukta etansulfonske kiseline prema zahtjevu 11.
13. Farmaceutski prihvatljiv adukt spoja s formulom (I) prema zahtjevu 1, naznačen time što je (R)-7-(3,4-Difluorbenzil)-6-(metoksimetil)-2-(5-metil-2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)-6,7-dihidroimidazo[1,2-a]pirazin-8(5H)-on adukt adipinske kiseline.
14. Kristalni oblik (R)-7-(3,4-Difluorbenzil)-6-(metoksimetil)-2-(5-metil-2-((1-metil-1H-pirazol-5-il)amino)pirimidin-4-il)-6,7-dihidroimidazo[1,2-a]pirazin-8(5H)-ona adukta adipinske kiseline prema zahtjevu 13.
15. Spoj prema bilo kojem od prethodnih zahtjeva, ili njegov farmaceutski prihvatljiv adukt, naznačen time što je za uporabu kao lijek.
16. Spoj prema bilo kojem od zahtjeva 1 do 14, ili njegov farmaceutski prihvatljiv adukt, naznačen time što je za uporabu u prevenciji ili liječenju raka kod toplokrvne životinje kao što je čovjek.
17. Spoj s Formulom (I), ili njegov farmaceutski prihvatljiv adukt, prema bilo kojem od zahtjeva 1 do 14 naznačen time što je za uporabu u liječenju NSCLC, karcinoma gušterače ili kolorektalnih karcinoma.
18. Farmaceutski pripravak naznačen time što sadrži spoj s formulom (I) ili njegov farmaceutski prihvatljiv adukt, prema bilo kojem od zahtjeva 1 do 14, te farmaceutski prihvatljiv razrjeđivač ili nosač.
19. Kombinacija pogodna za upotrebu u liječenju raka koja sadrži spoj s formulom (I) ili njegov farmaceutski prihvatljiv adukt, prema bilo kojem od zahtjeva 1 do 14, i drugo sredstvo protiv tumora.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252726P | 2015-11-09 | 2015-11-09 | |
| US201662401351P | 2016-09-29 | 2016-09-29 | |
| EP16791420.9A EP3374359B1 (en) | 2015-11-09 | 2016-11-08 | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
| PCT/EP2016/076932 WO2017080979A1 (en) | 2015-11-09 | 2016-11-08 | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200342T1 true HRP20200342T1 (hr) | 2020-06-12 |
Family
ID=57241113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200342TT HRP20200342T1 (hr) | 2015-11-09 | 2016-11-08 | Derivati dihidroimidazopirazinona korisni u liječenju raka |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US9902731B2 (hr) |
| EP (1) | EP3374359B1 (hr) |
| JP (1) | JP6877423B2 (hr) |
| KR (1) | KR20180074788A (hr) |
| CN (1) | CN108349983B (hr) |
| AU (1) | AU2016351813B2 (hr) |
| BR (1) | BR112018008397B1 (hr) |
| CA (1) | CA3003549A1 (hr) |
| CL (1) | CL2018001226A1 (hr) |
| CO (1) | CO2018004857A2 (hr) |
| CR (1) | CR20180316A (hr) |
| CY (1) | CY1123627T1 (hr) |
| DK (1) | DK3374359T3 (hr) |
| EA (1) | EA038028B1 (hr) |
| ES (1) | ES2780650T3 (hr) |
| HR (1) | HRP20200342T1 (hr) |
| IL (1) | IL258953A (hr) |
| LT (1) | LT3374359T (hr) |
| ME (1) | ME03770B (hr) |
| MX (1) | MX376639B (hr) |
| MY (1) | MY197626A (hr) |
| NI (1) | NI201800058A (hr) |
| PE (1) | PE20181288A1 (hr) |
| PH (1) | PH12018500987A1 (hr) |
| PL (1) | PL3374359T3 (hr) |
| PT (1) | PT3374359T (hr) |
| RS (1) | RS60155B1 (hr) |
| SG (1) | SG11201803066VA (hr) |
| SI (1) | SI3374359T1 (hr) |
| SM (1) | SMT202000152T1 (hr) |
| SV (1) | SV2018005687A (hr) |
| TN (1) | TN2018000119A1 (hr) |
| TW (1) | TWI730012B (hr) |
| WO (1) | WO2017080979A1 (hr) |
| ZA (1) | ZA201803742B (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10457669B2 (en) | 2015-10-21 | 2019-10-29 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
| KR20180074788A (ko) * | 2015-11-09 | 2018-07-03 | 아스트라제네카 아베 | 암의 치료에 유용한 디하이드로이미다조피라지논 유도체 |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| EP3845538B1 (en) * | 2018-10-10 | 2023-11-08 | Shenzhen TargetRx, Inc. | Dihydroimidazopyrazinone compound, composition including same, and use thereof |
| WO2020192750A1 (zh) | 2019-03-28 | 2020-10-01 | 江苏恒瑞医药股份有限公司 | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 |
| CN113825757B (zh) | 2019-05-24 | 2023-10-20 | 江苏恒瑞医药股份有限公司 | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 |
| CA3140475A1 (en) * | 2019-06-06 | 2020-12-10 | Wei-Guo Su | Tricyclic compounds and their use |
| US20230046093A1 (en) * | 2019-12-05 | 2023-02-16 | Astrazeneca Ab | Process and intermediates for the production of formula (i) |
| EP4071155A4 (en) * | 2019-12-06 | 2024-01-17 | D3 Bio (Wuxi) Co., Ltd. | THIAZOLOLACTAM COMPOUND USED AS ERK INHIBITOR AND USE THEREOF |
| JP2023543080A (ja) | 2020-09-29 | 2023-10-12 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | ピロロ複素環系誘導体の結晶及びその製造方法 |
| AR126166A1 (es) * | 2021-06-18 | 2023-09-27 | Antengene Discovery Ltd | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos |
| WO2022268065A1 (en) * | 2021-06-22 | 2022-12-29 | Fochon Biosciences, Ltd. | Compounds as erk inhibitors |
| WO2023008462A1 (ja) | 2021-07-27 | 2023-02-02 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2023081860A1 (en) | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Triazine amino derivatives for treating sca3 |
| EP4514806A1 (en) | 2022-04-27 | 2025-03-05 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| EP4522623A1 (en) | 2022-05-12 | 2025-03-19 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
| WO2024006971A2 (en) * | 2022-07-01 | 2024-01-04 | The Scripps Research Institute | Antimalarial compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| AU2003278377A1 (en) * | 2002-11-06 | 2004-06-07 | Merck Sharp And Dohme Limited | Imidazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic |
| GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| MX2009006864A (es) * | 2006-12-20 | 2009-08-28 | Schering Corp | Inhibidores novedosos de c jun-n-terminal cinasas. |
| EA022409B1 (ru) * | 2010-12-22 | 2015-12-30 | Янссен Фармацевтика Нв | Производные 5,6-дигидроимидазо[1,2-а]пиразин-8-иламина, пригодные в качестве ингибиторов бета-секретазы (васе) |
| JP2015531401A (ja) * | 2011-10-10 | 2015-11-02 | ハー・ルンドベック・アクチエゼルスカベット | イミダゾピラジノン骨格を有するｐｄｅ９ｉ |
| JP2013166727A (ja) * | 2012-02-16 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロイミダゾピラジノン誘導体 |
| PT3321262T (pt) | 2012-03-01 | 2021-03-04 | Array Biopharma Inc | Inibidores de serina/treonina quinases |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| SG11201604573WA (en) * | 2013-12-06 | 2016-07-28 | Genentech Inc | Serine/threonine kinase inhibitors |
| MX370906B (es) | 2013-12-30 | 2020-01-09 | Genentech Inc | Inhibidores de serina/treonina cinasa. |
| JP6642942B2 (ja) * | 2013-12-30 | 2020-02-12 | アレイ バイオファーマ、インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| MY196320A (en) | 2014-04-09 | 2023-03-24 | Genentech Inc | Process for the Manufacturing of Medicaments |
| US10412619B2 (en) * | 2014-11-14 | 2019-09-10 | Qualcomm Incorporated | Buffer status report for eDCS |
| WO2016162325A1 (en) * | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| WO2016192064A1 (en) | 2015-06-03 | 2016-12-08 | Js Innopharm (Shanghai) Ltd. | Heterocyclic compounds for treating psoriasis |
| CN107849046B (zh) | 2015-06-03 | 2020-06-12 | 常州捷凯医药科技有限公司 | 作为erk抑制剂的杂环化合物 |
| KR20180074788A (ko) * | 2015-11-09 | 2018-07-03 | 아스트라제네카 아베 | 암의 치료에 유용한 디하이드로이미다조피라지논 유도체 |
-
2016
- 2016-11-08 KR KR1020187016091A patent/KR20180074788A/ko not_active Withdrawn
- 2016-11-08 RS RS20200392A patent/RS60155B1/sr unknown
- 2016-11-08 HR HRP20200342TT patent/HRP20200342T1/hr unknown
- 2016-11-08 ME MEP-2020-72A patent/ME03770B/me unknown
- 2016-11-08 DK DK16791420.9T patent/DK3374359T3/da active
- 2016-11-08 LT LTEP16791420.9T patent/LT3374359T/lt unknown
- 2016-11-08 SG SG11201803066VA patent/SG11201803066VA/en unknown
- 2016-11-08 MY MYPI2018000675A patent/MY197626A/en unknown
- 2016-11-08 PE PE2018000611A patent/PE20181288A1/es unknown
- 2016-11-08 BR BR112018008397-6A patent/BR112018008397B1/pt active IP Right Grant
- 2016-11-08 PT PT167914209T patent/PT3374359T/pt unknown
- 2016-11-08 EP EP16791420.9A patent/EP3374359B1/en active Active
- 2016-11-08 ES ES16791420T patent/ES2780650T3/es active Active
- 2016-11-08 TN TNP/2018/000119A patent/TN2018000119A1/en unknown
- 2016-11-08 CR CR20180316A patent/CR20180316A/es unknown
- 2016-11-08 CN CN201680064567.2A patent/CN108349983B/zh active Active
- 2016-11-08 EA EA201891063A patent/EA038028B1/ru unknown
- 2016-11-08 WO PCT/EP2016/076932 patent/WO2017080979A1/en not_active Application Discontinuation
- 2016-11-08 AU AU2016351813A patent/AU2016351813B2/en active Active
- 2016-11-08 JP JP2018522784A patent/JP6877423B2/ja active Active
- 2016-11-08 SI SI201630668T patent/SI3374359T1/sl unknown
- 2016-11-08 PL PL16791420T patent/PL3374359T3/pl unknown
- 2016-11-08 CA CA3003549A patent/CA3003549A1/en active Pending
- 2016-11-08 US US15/345,537 patent/US9902731B2/en active Active
- 2016-11-08 SM SM20200152T patent/SMT202000152T1/it unknown
- 2016-11-08 TW TW105136236A patent/TWI730012B/zh not_active IP Right Cessation
- 2016-11-08 MX MX2018005725A patent/MX376639B/es active IP Right Grant
-
2018
- 2018-01-18 US US15/873,965 patent/US10202391B2/en active Active
- 2018-04-26 IL IL258953A patent/IL258953A/en active IP Right Grant
- 2018-05-03 NI NI201800058A patent/NI201800058A/es unknown
- 2018-05-07 CO CONC2018/0004857A patent/CO2018004857A2/es unknown
- 2018-05-07 CL CL2018001226A patent/CL2018001226A1/es unknown
- 2018-05-07 SV SV2018005687A patent/SV2018005687A/es unknown
- 2018-05-07 PH PH12018500987A patent/PH12018500987A1/en unknown
- 2018-06-06 ZA ZA2018/03742A patent/ZA201803742B/en unknown
-
2020
- 2020-04-02 CY CY20201100314T patent/CY1123627T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200342T1 (hr) | Derivati dihidroimidazopirazinona korisni u liječenju raka | |
| CO2019006598A2 (es) | Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3- d]pirimidina como inhibidores de kras g12c para tratar el cáncer de pulmón, pancreático o colorrectal | |
| JP2019503337A5 (hr) | ||
| HRP20191268T1 (hr) | Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk | |
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| CY1125460T1 (el) | Ενωσεις ιμιδαζο [4,5-d]πυρρολο [2,3-β]πυριδινης ως αναστολεις κινασων janus | |
| NZ627277A (en) | Imidazopyrrolidinone compounds | |
| PH12016501164A1 (en) | Heteroaryl substituted nicotinamide compounds | |
| HK1202541A1 (en) | 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors | |
| PH12014502886A1 (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| JP2016529292A5 (hr) | ||
| NZ629189A (en) | Liver x receptor modulators | |
| RS53898B1 (en) | QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | |
| EA201991109A1 (ru) | ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| JP2017527548A5 (hr) | ||
| NZ629230A (en) | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one | |
| HRP20181008T1 (hr) | Terapeutski aktivni pirazolo-pirimidin derivati | |
| JP2018537408A5 (hr) | ||
| JP2016537384A5 (hr) | ||
| PH12017500159B1 (en) | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | |
| HRP20151419T1 (hr) | Derivati 2-okso-1-imidazolidinil imidazotiadiazola | |
| EA201990973A1 (ru) | СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2 | |
| JP2016517877A5 (hr) | ||
| NZ714742A (en) | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use | |
| JP2016500109A5 (hr) |